Abbonarsi

Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3-year randomized controlled trial - 27/09/17

Doi : 10.1016/j.jaci.2016.10.050 
Roberto Berni Canani, MD, PhD a, b, c, , Margherita Di Costanzo, MD a, Giorgio Bedogni, MD c, d, Antonio Amoroso, BS a, c, Linda Cosenza, MD a, Carmen Di Scala, LDN a, Viviana Granata, MD a, Rita Nocerino, RN a, c
a Department of Translational Medical Science, University of Naples “Federico II”, Naples, Italy 
b European Laboratory for the Investigation of Food-Induced Diseases, University of Naples “Federico II”, Naples, Italy 
c CEINGE Advanced Biotechnologies, University of Naples “Federico II”, Naples, Italy 
d Clinical Epidemiology Unit, Liver Research Center Basovizza, Trieste, Italy 

Corresponding author: Roberto Berni Canani, MD, PhD, Pediatric Allergy Unit, Department of Translational Medical Science–Pediatric Section, European Laboratory for the Investigation of Food Induced Diseases, CEINGE–Advanced Biotechnologies, University of Naples “Federico II,” Via S. Pansini 5, 80131 Naples, Italy.Pediatric Allergy UnitDepartment of Translational Medical Science–Pediatric SectionEuropean Laboratory for the Investigation of Food Induced DiseasesCEINGE–Advanced BiotechnologiesUniversity of Naples “Federico II,”Via S. Pansini 5Naples80131Italy

Abstract

Background

Children with cow's milk allergy (CMA) have an increased risk of other allergic manifestations (AMs).

Objective

We performed a parallel-arm randomized controlled trial to test whether administration of an extensively hydrolyzed casein formula (EHCF) containing the probiotic Lactobacillus rhamnosus GG (LGG) can reduce the occurrence of other AMs in children with CMA.

Methods

Children with IgE-mediated CMA were randomly allocated to the EHCF or EHCF+LGG groups and followed for 36 months. The main outcome was occurrence of at least 1 AM (eczema, urticaria, asthma, and rhinoconjunctivitis). The secondary outcome was tolerance acquisition, which was defined as the negativization of a double-blind food challenge results at 12, 24, and 36 months. AMs were diagnosed according to standardized criteria. Tolerance acquisition was evaluated every 12 months.

Results

A total of 220 children (147 boys [67%]) with a median age of 5.0 months (interquartile range, 3.0-8.0 months) were randomized; 110 children were placed in the EHCF group, and 110 children were placed in the EHCF+LGG group. In the complete case analysis the absolute risk difference for the occurrence of at least 1 AM over 36 months was −0.23 (95% CI, −0.36 to −0.10; P < .001), and the absolute risk difference for the acquisition of cow's milk tolerance was 0.20 (95% CI, 0.05-0.35; P < .01) at 12 months, 0.24 (95% CI, 0.08-0.41; P < .01) at 24 months, and 0.27 (95% CI, 0.11-0.43; P < .001) at 36 months. In the sensitivity analysis the effect size of the main outcome was virtually unchanged when the occurrence of AMs was assigned to all 27 missing children.

Conclusions

EHCF+LGG reduces the incidence of other AMs and hastens the development of oral tolerance in children with IgE-mediated CMA.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Eczema, urticaria, asthma, rhinoconjunctivitis, atopic march, food allergy, gut microbiota, probiotics

Abbreviations used : AM, ARD, BRM, CCA, CMA, DBPCFC, EHCF, FA, FP, HDAC, IQR, LGG, RCT, SA-BCS, SA-EQS, SA-WCS, SPT


Mappa


 Supported in part by the Italian Ministry of Health (grant PE-2011-02348447) and an unrestricted grant from Mead Johnson Nutrition (Evansville, Ind) devoted to the Department of Translational Medical Science of the University of Naples “Federico II.” However, the Italian Ministry of Health and Mead Johnson Nutrition had no influence on (1) the study design; (2) the collection, analysis, and interpretation of the data; (3) the writing of the manuscript; or (4) the decision to submit the manuscript for publication.
 Disclosure of potential conflict of interest: All authors declare that all of their institutions have received grants from the Italian Ministry of Health (grant PE-2011-02348447) and an unrestricted grant from Mead Johnson Nutrition (Evansville, Ind) R. Berni Canani has received support for travel from Mead Johnson Nutrition.


© 2017  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 139 - N° 6

P. 1906 - giugno 2017 Ritorno al numero
Articolo precedente Articolo precedente
  • Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy
  • Raphaela Freidl, Antonia Gstoettner, Ulrike Baranyi, Ines Swoboda, Frank Stolz, Margarete Focke-Tejkl, Thomas Wekerle, Ronald van Ree, Rudolf Valenta, Birgit Linhart
| Articolo seguente Articolo seguente
  • Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome
  • Masatoshi Takagi, Shohei Ogata, Hiroo Ueno, Kenichi Yoshida, Tzuwen Yeh, Akihiro Hoshino, Jinhua Piao, Motoy Yamashita, Mai Nanya, Tsubasa Okano, Michiko Kajiwara, Hirokazu Kanegane, Hideki Muramatsu, Yusuke Okuno, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Yuki Bando, Motohiro Kato, Yasuhide Hayashi, Satoru Miyano, Kohsuke Imai, Seishi Ogawa, Seiji Kojima, Tomohiro Morio

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.